Fig. 1

ERp29 deficiency potentiates platelet function. (A-C) ERp29-deficient platelets have enhanced thrombin-induced P-selectin expression (A), activation of αIIbβ3 (detected by the JON/A activation-dependent antibody) (B) and Fibrinogen binding (C). Representative line graphs (left panels) and combined results (right panels); Data are presented as mean ± standard error of the mean (SEM), n = 3 for each group, *P <.05, **P <.01, ****P <.0001, Student’s t test. ns, not significant. (D-G) Representative aggregation and ATP release tracings (left panels) and combined results (right) showing the enhanced aggregation and ATP release in ERp29-deficient platelets using (D) thrombin, (E) U46619, (F) Convulxin and (G) CRP; Mean ± SEM, n = 3 for each group, **P <.01, ***P <.001, ****P <.0001, Student’s t test. Aggregation and ATP secretion were monitored in the lumi-aggregometer